亚洲晚期黑色素瘤患者BRAF联合MEK抑制剂治疗的112例结局分析
该回顾性多中心研究分析了日本16家机构112例接受BRAF联合MEK抑制剂(B+Minh)治疗的晚期黑色素瘤患者,总体缓解率75.0%,肢端/黏膜型与皮肤型缓解率无统计学差异,既往免疫检查点抑制剂(ICI)使用不影响B+Minh缓解,但B+Minh后ICI缓解率仅20%,脑是最常见复发部位(17.9%)。
要点
- B+Minh在包括肢端/黏膜型的日本晚期黑色素瘤患者中有效,总体缓解率75.0%。
- 既往ICI治疗不影响B+Minh缓解,但B+Minh后ICI缓解率仅20%。
- 脑是最常见复发部位(17.9%),治疗期间需警惕脑转移。
核心结论
- B+Minh对日本晚期黑色素瘤患者有效,包括肢端/黏膜型,生存相关因素与西方研究相似。
研究设计与样本
- 回顾性多中心研究,收集日本16家机构144例记录,最终分析112例接受B+Minh(达拉非尼+曲美替尼或恩考芬尼+比美替尼)的晚期黑色素瘤患者。
主要发现
- 整个队列缓解率为75.0%。
- 肢端/黏膜型与皮肤型缓解率分别为64.3%与76.5%,无统计学差异。
- 既往ICI治疗者与未治疗者B+Minh缓解率分别为72.7%与73.9%,无差异;B+Minh后ICI缓解率仅20%。
- 达到完全缓解者24个月总生存率最佳,为94.7%。
- 血清乳酸脱氢酶升高和转移部位≥3个与生存独立相关;最常见复发部位为脑(17.9%)。
关键数值与推荐
- 总体缓解率75.0%;肢端/黏膜型64.3%,皮肤型76.5%。
- 既往ICI治疗者B+Minh缓解率72.7%,未治疗者73.9%;B+Minh后ICI缓解率20%。
- 完全缓解者24个月总生存率94.7%。
- 脑复发率17.9%;3/4级发热发生率58.8%。
临床怎么用
- B+Minh可用于日本晚期黑色素瘤患者,包括肢端/黏膜型。
- 既往ICI治疗不影响B+Minh疗效,但B+Minh后ICI缓解率低,序贯治疗需权衡。
- B+Minh治疗期间应警惕脑转移,脑为最常见复发部位。
局限性
- 回顾性研究设计。
- 样本量有限,仅分析112例。
- 肢端/黏膜型病例数较少(14例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: As most clinical trials evaluating BRAF and MEK inhibitor combination therapy (B + Minh) have been conducted in Western countries, little is known about the effect of B + Minh among East Asian populations. MATERIAL AND METHODS: Data from patients with advanced melanoma treated using B + Minh (either dabrafenib + trametinib or encorafenib + binimetinib) were retrospectively collected from 16 institutes in Japan. Response rates, adverse events, patterns of failure and survival were analysed. RESULTS: We analysed 112 of 144 collected patient records and, of these, 14 had acral/mucosal melanoma. The response rate for the entire cohort was 75.0%. There were no statistical differences in response rates between acral/mucosal and cutaneous melanomas (64.3% versus 76.5%), whereas previous treatment using immune checkpoint inhibitors (ICIs) did not affect response (72.7% versus 73.9%) to B + Minh, response to ICI after B + Minh was only 20%. Patients who achieved complete response had the best overall survival rates at 24 months (94.7%). Elevated serum lactate dehydrogenase levels and 3 or more metastatic sites were independently associated with survival. The most common relapse site was the brain (17.9%). More than half of the patients (58.8%) experienced grade III/IV pyrexia. CONCLUSION: B + Minh was effective among Japanese patients with melanoma, including those with acral/mucosal melanoma. Factors associated with survival were similar to previous Western studies. B + Minh response was not affected by the previous use of ICI; however, vigilance against brain metastasis during B + Minh therapy is required as the brain was our most commonly encountered relapse site.
引用
- Fujisawa Y, Ito T, Kato H, et al. Outcome of combination therapy using BRAF and MEK inhibitors among Asian patients with advanced melanoma: An analysis of 112 cases. Eur J Cancer. 2021. PMID: 33503528. doi:10.1016/j.ejca.2020.12.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。